Atlantic Healthcare outlines filing plans

December 16, 2016 Christoph Graener

 

Toby Wilson Waterworth, CEO of Atlantic Healthcare, speaks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company’s recent fundraising and next stages of development for the business.
Wilson Waterworth also outlines Atlantic’s development and filing plans for lead product, alicaforsen, for the treatment of pouchitis—a condition for which there are currently no approved treatments. Atlantic has an exclusive licensing agreement with Ionis Pharmaceuticals Inc. (formerly ISIS Pharmaceuticals) for the global rights to alicaforsen, for which it has several preclinical and clinical programs ongoing in ulcerative colitis and other gastrointestinal disorders.

  

  

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Toby Wilson Waterworth – CEO, Atlantic Healthcare

 

Previous Article
InflaRX CEO highlights pipeline goals
InflaRX CEO highlights pipeline goals

InflaRX is developing highly specific monoclonal antibodies targeting activation products of the complement...

Next Article
Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos
Vaximm seeks pharma partners for T-cell/checkpoint inhibitor combos

Dr. Matthias Schroff, the new CEO of privately-held Swiss vaccines company Vaximm, talks about how the comp...